Impact Biomedical (IBO) Capital Expenditures (2023)

Impact Biomedical (IBO) posted Capital Expenditures of $1000.0 for Q3 2023, down 91.67% on a QoQ basis from $12000.0 in Q2 2023.

Impact Biomedical (IBO) Capital Expenditures (2023) Analysis & Trends

Impact Biomedical's Capital Expenditures history runs 1 years deep, the most recent figure standing at $1000.0 for Q3 2023.

Quarterly Capital Expenditures changed N/A year-over-year to $1000.0 in Q3 2023, while the trailing twelve-month figure through Dec 2023 was $18000.0 (changed N/A YoY) and the FY2023 annual result came in at $18000.0, down 93.48% from the prior year.
Capital Expenditures was $1000.0 for Q3 2023 at Impact Biomedical, down from $12000.0 in the prior quarter.
Across five years, Capital Expenditures topped out at $12000.0 in Q2 2023 and bottomed at $1000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capital Expenditures (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-8,939.03
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	43.25 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	133.40 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	230.60 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	786,000.00
10	Impact Biomedical	47.44 Mn	50.67 Mn	-	-

Download Data